What MAS-ER Treats: Main Uses and Benefits

MAS-ER is commonly used across domains where additional symptomatic support is needed, assisting in the management of symptoms that interfere with daily functioning. This medication is formally indicated for use in two primary chronic conditions: Attention-Deficit Hyperactivity Disorder (ADHD) and Narcolepsy.

---

Support for Focus, Alertness, and Behavioral Control

This medication is applied in managing symptoms related to Core Executive Function Deficits, such as difficulty with concentration and organization, which may interfere with academic or occupational stability. It is also considered relevant in clinical settings marked by the heightened symptom of Severe Daytime Sleepiness characteristic of Narcolepsy, as it offers supportive symptomatic relief that helps sustain alertness. Furthermore, MAS-ER plays a role in addressing symptom clusters of hyperactivity and impulsivity, assisting with self-control and contributing to easing the symptom load.

“MAS-ER is commonly used when short-term symptomatic assistance is needed to help maintain a sense of stability when symptoms are more noticeable.”

This supportive therapeutic approach is applied in clinical settings that involve acute or unstable symptom patterns associated with chronic conditions.

---

Quick Fact: Symptomatic Support for Sleepiness MAS-ER is relevant for easing symptoms linked to Severe Daytime Sleepiness, providing support that helps improve day-to-day comfort during symptomatic periods associated with Narcolepsy.

MAS-ER use is officially established and approved for children starting at age six, adolescents, and adults.

The medicine is contraindicated (must not be used) in several specific populations due to the risk of severe reactions. These absolute exclusions include individuals with symptomatic cardiovascular disease, such as moderate to severe hypertension, advanced arteriosclerosis, or structural cardiac abnormalities. MAS-ER is also prohibited for patients with hyperthyroidism, glaucoma, or agitated states. Use is strictly forbidden for anyone taking a monoamine oxidase inhibitor (MAOI) or within 14 days of discontinuing an MAOI. Additionally, individuals with a known hypersensitivity to amphetamine or related sympathomimetic amines must not use this medication.

Use is generally not recommended in several special populations. This includes children under six and the geriatric population, as clinical efficacy has not been studied or established for these age groups. Patients with End Stage Renal Disease (ESRD) should not use MAS-ER. Those with severe renal impairment require an adjusted dose. For pregnant individuals, use may be permitted only if the potential benefit outweighs the potential risk to the fetus, and breastfeeding is not recommended.

Interaction Map: Interactions with other medicines and products — official regulatory information for MAS-ER

Category	Details (As stated in regulatory documents)
Medicinal product categories with documented interactions	Monoamine Oxidase Inhibitors (MAOIs), CYP2D6 Inhibitors, Serotonergic Agents, Adrenergic Blockers, Alkalinizing Agents (GI and Urinary), Acidifying Agents (GI and Urinary), Tricyclic Antidepressants [Source 1.4, 2.1].
Specific interacting medicines (if explicitly listed)	Linezolid, Methylene Blue (with MAOI activity), Triptans, Fentanyl, Lithium, Tramadol, St. John’s Wort, Sodium Bicarbonate, Acetazolamide, Ascorbic Acid, Ammonium Chloride [Source 1.6, 2.1].
Mechanistic basis of interactions (only if stated in label)	Inhibition of CYP2D6 (leading to increased exposure); Serotonergic system enhancement (leading to increased risk); Urinary/GI pH modification (leading to altered excretion/blood levels); Opposing physiological effects [Source 1.4, 2.1].
Timing-based interaction rules (if applicable)	MAS-ER must not be administered during or within 14 days following the use of an MAOI [Source 1.6, 2.1].
Population-specific interaction notes (if applicable)	In adult patients with severe renal impairment (eGFR < 30 mL/min/1.73 m^2), a specific maximum dose restriction is noted due to reduced clearance [Source 2.1].
Interaction-related restrictions	Contraindicated with MAOIs; use with caution when co-administering with serotonergic agents [Source 1.4, 1.6, 2.1].

Official Interaction Statements

• Co-administration with MAO Inhibitors is contraindicated due to the risk of hypertensive crisis and hyperpyrexia, with a mandatory separation of 14 days.
• Medicines that inhibit the CYP2D6 enzyme may increase the plasma concentration of MAS-ER, classifying this as a pharmacokinetic interaction.
• Co-administration with other serotonergic agents carries a regulatory warning for increased risk of Serotonin Syndrome.
• Acidifying agents (including certain foods and supplements) can reduce the blood levels of MAS-ER by increasing urinary excretion, while alkalinizing agents have the opposite effect.

Connection to the overall interaction profile

Regulatory documents define the product's interaction structure primarily through two critical categories: absolute contraindication with MAOIs, and clinically significant interactions driven by either pharmacokinetic alterations (CYP2D6 inhibition, urinary pH changes) or additive pharmacodynamic effects (serotonergic risk). This profile establishes the specific substance classes and environmental factors that formally alter the exposure or physiological effects of MAS-ER, detailing the necessary constraints for co-administration. (195 words)

How MAS-ER Works

The action of MAS-ER is fundamentally driven by its ability to precisely modulate central nervous system (CNS) neurotransmitter activity through targeted protein interaction.

---

Core Mechanism: Reverse Transport and Catecholamine Surge

The drug primarily targets the Dopamine Transporter (DAT) and the Norepinephrine Transporter (NET). Instead of simply blocking reuptake, MAS-ER acts as a substrate, reversing the function of these transporters to actively force high levels of dopamine and norepinephrine from the neuron into the synaptic cleft. This sustained surge of catecholamines is the fundamental mechanistic cascade that defines the drug's physiological effect profile.

---

Pharmacological Synergy of Dual Enantiomers

MAS-ER achieves a broad spectrum of physiological modulation by combining both the dextro- (d-enantiomer) and levo- (l-enantiomer) forms of amphetamine. The d-enantiomer preferentially enhances dopaminergic signaling related to executive function, while the l-enantiomer has a relatively stronger influence on the noradrenergic system, increasing activity related to alertness. This synergy results in a balanced physiological activation that encompasses both dopaminergic and noradrenergic modulation.

---

Functional Consequence: Prefrontal Cortex Enhancement

The enhanced catecholamine signaling is most functionally relevant in the Prefrontal Cortex (PFC), the brain region governing cognitive control. By stimulating Dopamine D1 and alpha2-Adrenergic receptors in the PFC, the mechanism alters the brain's capacity to modulate competing neural signals and maintain stable activity. This results in a state of elevated CNS activity that influences core cognitive processes.

Oral Administration and Scheduling

MAS-ER is formulated as an Oral Capsule for Extended-Release (ER) delivery. Official instructions mandate that the medicine be administered once daily in the morning upon awakening to align with its duration of action. The capsule may be taken with or without food, but consistently maintaining the same intake routine (e.g., always with food) is recommended.

Official Dosing Pattern and Titration

Use of the medicine follows a structured protocol beginning with a low dose, typically 12.5 mg once daily, to establish the optimal regimen. Dosage adjustment must occur through a gradual titration process, where increments of 12.5 mg are permitted no sooner than weekly (not less than seven days apart). The established maximum daily dosage is 50 mg. If a dose is missed in the morning, the official instruction is to not administer the dose later in the day.

Capsule Handling and Special Limits

The capsule should be swallowed whole. If swallowing is difficult, the entire contents of the capsule may be opened and sprinkled over a spoonful of applesauce and consumed immediately; the contents must not be divided, stored, or chewed. Population-specific limits on the maximum dose are defined, particularly for individuals with kidney impairment:

Population Group	Maximum Daily Dose Limit
Adults with Severe Renal Impairment	25 mg daily
Pediatrics (13-17) with Severe Renal Impairment	12.5 mg daily
End-Stage Renal Disease (ESRD)	Not recommended

These instructions define the standardized, label-based approach for the proper administration of the medicine.

Research evidence / Overview of studies for MAS-ER

Evidence Base for Attention-Deficit Hyperactivity Disorder (ADHD)

The primary body of evidence for the use of MAS-ER in ADHD comes from short-term, placebo-controlled Randomized Controlled Trials (RCTs). These studies research explored how symptoms changed over defined time intervals in observed populations, including both pediatric (children and adolescents) and adults. Studies primarily measured scores on standardized, clinician-rated instruments for inattention and hyperactivity/impulsivity. Research also examined performance on tasks in controlled settings, monitoring outcomes reflecting performance measures or activity level.

Studies reported measurements of core ADHD symptom scores that were compared to those observed in the non-active placebo group. The key limitation is that the majority of the pivotal efficacy trials were designed as short-term studies, typically lasting only a few weeks. Long-term functional outcomes are not fully established by dedicated, multi-year randomized research. The specific data for the long-term use of this extended-release formulation remain insufficient.

---

Evidence Base for Narcolepsy

MAS-ER was evaluated in clinical research exploring its effects in conditions associated with acute or disruptive episodes of excessive sleepiness. These studies focused on outcomes related to systemic or functional imbalance by monitoring objective and subjective measures of wakefulness and alertness. Studies monitored patient-reported outcomes describing perceived discomfort linked to daytime sleepiness.

The research available specifically for this extended-release formulation's use in Narcolepsy is more limited in volume compared to the evidence base for the ADHD indication. The available evidence also relies on extrapolation from earlier studies of the immediate-release formulation, given the established history of stimulants for this use.

---

Known Research Gaps and Areas of Uncertainty

The research provides insight into short-term changes and helps contextualize how patients reported their experience in controlled settings, but evidence highlights what is known — and what is still uncertain. A main research gap is the limited information for long-term outcomes that extends beyond the few weeks of the primary clinical trials. Another key gap is that data are still emerging for how consistently the findings generalize to individuals with more severe or complex medical profiles.

Common questions about MAS-ER (FAQ)

Q: Can the effectiveness of MAS-ER decrease over time?

Studies used to establish the effectiveness of MAS-ER and similar medications are primarily short-term in nature. Official prescribing information states that data concerning the long-term maintenance of the drug's effects are limited. Like all medicines in its class, official documents note that chronic use of amphetamines is associated with the risk of abuse and dependence.

Q: Is MAS-ER safe to use during pregnancy?

Regulatory documents state that using MAS-ER during pregnancy may cause harm to the fetus, and newborns exposed to amphetamines may experience withdrawal symptoms after birth. Regulatory documents describe that use may be considered only if the potential benefit is judged to outweigh the potential risk to the fetus.

Q: Do older adults need a different approach to using MAS-ER?

The safety and effectiveness of MAS-ER have not been established in older adults (aged 65 and over). Official clinical trials did not include enough geriatric patients to establish a specific approach for this age group, and official information does not recommend use in this population.

Q: Can MAS-ER be used by people with kidney problems?

Use of MAS-ER is limited for individuals with certain kidney conditions. Regulatory documents define specific maximum daily dose restrictions for individuals with severe renal impairment (reduced kidney function). Use is explicitly not recommended for those with End-Stage Renal Disease (ESRD), as the medicine has not been studied in this population.

Q: What kind of monitoring is typically done when using MAS-ER?

Official product information describes the requirement to closely monitor certain health metrics while a patient is using MAS-ER. This includes checking blood pressure and heart rate regularly in all patients. In pediatric patients, regulatory documents indicate a need to monitor growth, including height and weight, due to associated risks.

Q: Does MAS-ER help with long-term conditions?

MAS-ER is approved for treating conditions such as Attention-Deficit Hyperactivity Disorder (ADHD), which are typically managed chronically. However, the key efficacy trials that established the drug's initial approval were primarily designed as short-term studies.

Q: How quickly does MAS-ER usually start to work?

MAS-ER is an extended-release medicine, meaning the active ingredients are released over time. Pharmacokinetic studies indicate that the maximum concentration of the drug in the blood is generally reached between 1.5 to 2 hours after taking the medicine.

Q: How long do the effects of one use of MAS-ER typically last?

The extended-release formulation is designed to provide effects over an extended period to support a once-daily schedule. Pharmacokinetic data indicates that the therapeutic effect of the extended-release formula can last for approximately 8 to 12 hours.

Q: Is it normal to feel tired after starting MAS-ER?

Tiredness or fatigue is not listed among the most common adverse reactions in the official prescribing information. However, regulatory documents do note the potential for asthenia, which is a general lack of energy or weakness, as an adverse reaction in some patient populations.

Q: Are there food or drinks that should be avoided when using MAS-ER?

Official information indicates that certain substances can affect how the body processes MAS-ER. Specifically, medicines and products that change the pH (acidity or alkalinity) of the stomach or urine may alter the amount of MAS-ER in the blood. For example, acidifying agents can lower blood levels, and alkalinizing agents can increase them.

Q: Why is MAS-ER only available by prescription?

MAS-ER is classified as a Schedule II controlled substance by regulatory bodies. This classification is due to its composition as a stimulant, which is associated with a high potential for abuse and dependence. This status legally requires that the medicine be available only with a prescription from a licensed healthcare provider.

Q: Does MAS-ER interact with alcohol?

Regulatory warnings for Central Nervous System (CNS) stimulants contain warnings regarding the use of the medicine with other CNS depressants. Combining these substances is noted to potentially increase the risk of serious side effects, as alcohol is classified as a CNS depressant.

Q: Can MAS-ER be used to treat things other than its main approved uses?

MAS-ER is approved by regulatory agencies for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. The medicine is not approved for any other uses in the official prescribing information.

Q: Does MAS-ER cause any changes in mood or behavior?

Official documents list several potential effects on mood and behavior. Adverse reactions include emotional lability (rapid changes in mood), agitation, and nervousness. The label also contains a warning about the potential for the emergence or worsening of Psychotic or Manic Symptoms.

Q: What is the recommended storage temperature for MAS-ER?

MAS-ER must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). Due to its classification, the medicine should always be kept in a safe, secure place to prevent unauthorized access and strictly out of the reach of children.

Q: What are the common reasons people stop using MAS-ER?

Clinical trial data indicate that some patients stop using MAS-ER because of specific adverse reactions. The most common effects reported during trials that led to patients discontinuing the use of the medicine were insomnia (difficulty sleeping) and weight loss.

Q: How soon after stopping other medicines can I start MAS-ER?

MAS-ER is contraindicated (must not be used) with a class of medicines called Monoamine Oxidase Inhibitors (MAOIs). Regulatory documents state that MAS-ER is contraindicated during or within 14 days following the use of an MAOI, due to the risk of hypertensive crisis and hyperpyrexia.

Q: Are there any known withdrawal effects when stopping MAS-ER?

The amphetamine class of drugs, to which MAS-ER belongs, is associated with a high potential for dependence. If the medicine is stopped suddenly after chronic, high-dose use, patients may experience symptoms like extreme fatigue and depression.

How to Store and Dispose of MAS-ER

MAS-ER Capsules are a Schedule II controlled substance, requiring strict adherence to regulatory storage and disposal rules to prevent misuse and ensure stability.

Official Storage Requirements

• Temperature: Store at Controlled Room Temperature between 20 C to 25 C (68 F to 77 F). Permitted excursions extend up to 30 C.
• Protection: The medicine must be protected from light and kept in a safe, secure place to prevent unauthorized access.
• Child Safety: MAS-ER must be stored strictly out of the reach of children.
• Stability: If the capsule contents are mixed with food for administration, the mixture must be consumed immediately and cannot be stored for later use.

Regulated Disposal Protocol

Unused or expired MAS-ER must be disposed of properly. The preferred method is using an authorized drug take-back program. If this is unavailable, the alternative, FDA-approved method requires mixing the product with an undesirable substance (such as dirt or used coffee grounds), sealing it in a container, and discarding it in the household trash.